Clomid and letrozole are both five-day oral fertility pills, and the choice between them is the first real decision most women face after an infertility diagnosis. The honest answer is that neither wins everywhere: letrozole is the better drug for polycystic ovary syndrome (PCOS), clomiphene holds its ground in unexplained infertility, and in a third group — women who already ovulate normally — the more important question is whether either drug is worth taking at all.
The two headline numbers people quote come from the same trial. In PPCOS II, 750 women with PCOS took up to five cycles: cumulative live birth was 27.5% on letrozole versus 19.1% on clomiphene — Legro et al., N Engl J Med, 2014. In AMIGOS, 900 women with unexplained infertility: live birth per cycle was 23.3% on clomiphene versus 18.7% on letrozole — Diamond et al., N Engl J Med, 2015.
Same two drugs, opposite verdicts, both statistically solid. The diagnosis decides.
How this article was researched: the ProIVF Medical Editorial Team worked from the FDA prescribing information for both drugs, the randomized trials that set current practice, Cochrane reviews and registry cohorts; every figure links to its primary source, and the ProIVF Medical Advisory Board reviewed the draft. Drug-specific detail lives in our guides to clomiphene and letrozole.
Clomid vs letrozole: which comes first, by diagnosis
| Your diagnosis | First choice | Why |
|---|---|---|
| PCOS, not ovulating | Letrozole | 27.5% vs 19.1% cumulative live birth over five cycles; now first-line in guidelines |
| Unexplained infertility, ovulating normally | Clomiphene (or gonadotropin) | 23.3% vs 18.7% live birth per cycle — letrozole did not win |
| Clomiphene-resistant PCOS | Letrozole, then injectables or laparoscopic ovarian drilling | A substantial minority of PCOS patients do not ovulate on clomiphene at all |
| Thin lining on clomiphene | Letrozole | Receptive endometrium in 77.5% of letrozole cycles |
| Male factor, off-label | Clomiphene | Larger evidence base for sperm parameters; letrozole data are thinner |
| Trying to minimise twins | Letrozole | Multiple-pregnancy risk ratio 0.42 versus clomiphene |
If you want one sentence: letrozole for PCOS, clomiphene for unexplained infertility, and letrozole again if clomiphene thinned your lining or failed to make you ovulate.
If you have PCOS, letrozole is no longer a preference — it is the guideline
Three independent evidence layers agree. PPCOS II randomized 750 women and found live birth in 103 of 374 letrozole cycles versus 72 of 376 clomiphene cycles (P=0.007); cumulative ovulation was 61.7% versus 48.3% of cycles (P<0.001). A Cochrane review of 41 trials and 6,522 women put the live-birth odds ratio at 1.72 (95% CI 1.40–2.11) in letrozole’s favour, with a number needed to treat of 10 — Cochrane, 2022. A 2023 meta-analysis of 29 trials and 3,952 women reported a live-birth risk ratio of 1.49 (1.27–1.74) — Liu et al., 2023.
A number needed to treat of 10 means that for every ten women switched from clomiphene to letrozole, one extra live birth appears. That is a large effect for a change that costs the same.
The advantage is not uniform across PCOS either — it grew with baseline testosterone in an individual-patient-data meta-analysis of 20 trials (interaction risk ratio 1.29, 95% CI 1.01–1.65) — Wang et al., 2019. Higher androgen levels, more reason to prefer letrozole.
If your diagnosis is unexplained infertility, clomiphene still holds
AMIGOS randomized 900 ovulatory women with unexplained infertility to up to four cycles of gonadotropin, clomiphene or letrozole. Live birth per cycle: 32.2% gonadotropin, 23.3% clomiphene, 18.7% letrozole. Letrozole was significantly worse than standard therapy (P=0.003) and worse than gonadotropin alone (P<0.001), though not significantly worse than clomiphene alone (P=0.10).
This is the finding most often skipped in “letrozole is the modern choice” articles. If you ovulate on your own and nobody can find a cause, the trial data do not support switching to letrozole for its own sake. What the same trial does support is injectable gonadotropins — at roughly three times the medication cost and a multiple-gestation rate of 32% versus 9% on clomiphene.
If you ovulate normally, the real question is different
Clomiphene has limited value in women with regular cycles and no ovulation problem: it adds side effects and twin risk without correcting a defect that is not there. Some clinicians still prescribe it as a low-cost first step before IVF. That is a defensible pragmatic choice, but it is not evidence-driven, and you are entitled to ask what it is expected to fix.
What is the actual difference between Clomid and letrozole?
They reach the same endpoint — more follicle-stimulating hormone (FSH) from the pituitary — by opposite routes.
| Clomiphene citrate (Clomid, Serophene) | Letrozole (Femara) | |
|---|---|---|
| Drug class | Selective estrogen receptor modulator (SERM) | Aromatase inhibitor |
| Mechanism | Blocks estrogen receptors in the hypothalamus and pituitary, so the brain reads estrogen as low | Blocks the enzyme that converts androgens to estrogen, so estrogen genuinely falls |
| Estrogen receptors elsewhere | Blocked — including in the endometrium and cervix | Not blocked; estrogen effect is reduced but receptor signalling stays intact |
| Standard dose | 50 mg daily × 5 days; escalate to 100 mg if no ovulation | 2.5 mg daily × 5 days (some protocols use 5 mg) |
| Half-life | Long; remains active for weeks | Short — roughly 2 days |
| Effect on uterine lining | Can thin it (7.3 ± 2.2 mm in one poor-responder cohort) | Preserves it (receptive pattern in 77.5% of cycles) |
| Typical twin rate | 6.9% twins in FDA trial pregnancies | 3.4% in PPCOS II |
| FDA status for ovulation induction | Approved | Off-label in the US (approved for breast cancer); standard of care nonetheless |
Why the mechanism difference changes your lining
This is the part that actually matters clinically. Clomiphene blocks estrogen receptors everywhere, including the endometrium, so a cycle can produce a good follicle and a lining too thin to implant. In a cohort of poor ovarian responders, endometrial thickness on clomiphene-based minimal stimulation was 7.3 ± 2.2 mm, against 11.4 ± 3.3 mm on mild and 12.9 ± 3.8 mm on conventional gonadotropin protocols (p < 0.0001) — JBRA Assist Reprod, 2018.
Letrozole lowers estrogen production instead of blocking the receptor, and the endometrium tolerates it better: a receptive pattern in 77.5% of letrozole cycles versus significantly fewer on clomiphene, with higher volume and blood-flow indices — Wang et al., 2019. In a randomized study of 160 women with PCOS, clinical pregnancy reached 30.0% with letrozole versus 13.8% with clomiphene, ongoing pregnancy 22.5% versus 10.0%.
If you had a good follicle on clomiphene and still did not conceive, ask what your lining measured. Under 7 mm, the answer may be the drug rather than the dose.
Are Clomid and letrozole the same drug? No — and the brand names confuse people
Clomid and Serophene are both clomiphene citrate. Femara is letrozole. They are different molecules, different classes, different doses and different side-effect profiles. “Clomid vs Femara” and “clomid vs letrozole” are the same comparison; so are “Serophene vs Femara”. A pharmacy substitution between them is never appropriate.
Letrozole vs Clomid: what the trials show, in one table
A ratio of 1.0 means no difference. Everything below is randomized or pooled randomized data.
| Outcome (letrozole vs clomiphene) | Result | Source |
|---|---|---|
| Cumulative live birth, 5 cycles, PCOS | 27.5% vs 19.1% (rate ratio 1.44, 95% CI 1.10–1.87) | PPCOS II, 2014 |
| Cumulative ovulation, PCOS | 61.7% vs 48.3% of cycles | PPCOS II, 2014 |
| Live birth, 29 RCTs / 3,952 women | RR 1.49 (1.27–1.74) | Liu, 2023 |
| Clinical pregnancy | RR 1.48 (1.34–1.63) | Liu, 2023 |
| Live birth, 20 RCTs / 3,962 women (IPD) | RR 1.43 (1.17–1.75) | Wang, 2019 |
| Time to pregnancy | Hazard ratio 1.72 (1.38–2.15) | Wang, 2019 |
| Live birth, 41 trials / 6,522 women | OR 1.72 (1.40–2.11); NNT 10 | Cochrane, 2022 |
| Multiple pregnancy | RR 0.42 (0.18–0.98) — lower with letrozole | Miller & Pinheiro, 2026 |
| Miscarriage | RR 0.97 (0.73–1.28) — no difference | Miller & Pinheiro, 2026 |
| Live birth per cycle, unexplained infertility | 18.7% vs 23.3% — clomiphene higher | AMIGOS, 2015 |
Read the bottom row before you read the top. Every favourable number above comes from PCOS populations; the one trial that enrolled ovulatory women with unexplained infertility points the other way.
Clomid vs letrozole for PCOS specifically
PCOS is where the comparison has a clear winner, and where the practical questions are hardest.
Clomiphene resistance: what to do when 100 mg does nothing
A substantial minority of women with PCOS does not ovulate on clomiphene at all, and a further share ovulates only at the 100 mg ceiling. The FDA label stops there — 50 mg, then 100 mg, and no higher. Past that point the options are, in order of evidence: switch to letrozole 2.5–5 mg; add metformin if you have insulin resistance; move to injectable gonadotropins with monitoring; or consider laparoscopic ovarian drilling.
Letrozole is the most efficient first move of those four, because it works through a different mechanism and does not depend on estrogen-receptor blockade that has already failed.
High BMI, high AMH, high testosterone
Three markers that shift the odds. High baseline testosterone favours letrozole, per the interaction analysis above. Very high AMH with severe PCOS predicts resistance to oral agents of either class, and a plan that assumes injectables will be needed. High BMI lowers response to both drugs and is the situation where dose escalation and monitored cycles matter most — our PCOS and IVF guide covers the full pathway when oral agents are exhausted.
Clomid vs letrozole for twins
If twin risk is a deciding factor for you, the data are unusually clean.
Clomiphene’s FDA label reports multiple gestation in 7.98% of trial pregnancies — 6.9% twins, 0.5% triplets, 0.3% quadruplets and 0.1% quintuplets. Singleton survival was 98.16% against 83.25% for multiple births. In PPCOS II, twins occurred in 7.4% of clomiphene pregnancies versus 3.4% of letrozole pregnancies, and the 2026 meta-analysis across 32 trials confirmed a multiple-pregnancy risk ratio of 0.42 (0.18–0.98) favouring letrozole — Miller & Pinheiro, 2026.
AMIGOS adds the comparison that matters most: multiple gestation in 13% of letrozole, 9% of clomiphene and 32% of gonadotropin pregnancies. Note the reversal — in that trial letrozole’s multiple rate was slightly higher than clomiphene’s, and every multiple in both arms was a twin. Twin rates are a function of how many follicles you grow, not of which drug you took; a clinic that does not cancel high-response cycles can produce twins on either.
Side effects: which one is easier to tolerate
PPCOS II found overall adverse events similar between the two drugs — the difference is in which side effects.
| Clomiphene (FDA label, n = 8,029) | Letrozole (2.5–5 mg) | |
|---|---|---|
| Hot flushes | 10.4% | Common — the most characteristic effect |
| Ovarian enlargement | 13.6% | Less common |
| Abdominal bloating | 5.5% | Less common |
| Nausea and vomiting | 2.2% | Possible |
| Breast discomfort | 2.1% | Possible |
| Visual symptoms (blurring, floaters, flashes) | 1.5% — stop and report | Not characteristic |
| Headache | 1.3% | Common, with dizziness and fatigue |
| Mood swings | Frequently reported | Less prominent |
| OHSS | Rare alone | Rare — zero cases in one 10-day cohort |
The visual-symptom rule
Clomiphene’s label warns that visual disturbance becomes more frequent with higher total dose and longer treatment. It is usually reversible, but cases have persisted after stopping. The rule is simple: new blurring, floaters, flashes or blind spots means stop the drug and call your clinician — do not wait for the cycle to finish.
Many women who could not tolerate clomiphene’s mood and visual effects do fine on letrozole, because the mechanism spares tissues outside the ovary. That is a legitimate reason to switch even when the live-birth data are neutral.
Birth defects: what the cohort data say
In 911 newborns from five Canadian centres, overall malformations were 4.8% after clomiphene versus 2.4% after letrozole, major malformations 3.0% versus 1.2%, and cardiac anomalies 1.8% versus 0.2% (P=0.02) — Tulandi et al., Fertil Steril, 2006. A 2024 cohort on post-conceptional clomiphene exposure found no increase in major malformations (crude RR 0.64, 95% CI 0.19–2.15) — Drug Saf, 2024.
Neither drug is a known teratogen. The signal, such as it is, runs in letrozole’s favour, and study designs differ enough that “reassuring but not proven” is the fair summary for both.
Can you take Clomid and letrozole together?
Patients ask this often, and the honest answer is: not as a self-directed combination, and not as a standard first-line protocol.
There is no randomized evidence that combining clomiphene and letrozole produces more live births than either alone. The combinations that do appear in practice are different: letrozole plus injectable FSH in a mild-stimulation or mini-IVF cycle, or clomiphene plus a trigger injection with timed intercourse or IUI. Those are clinician-designed protocols with monitoring, not two tablets taken together because one did not work.
Taking both simultaneously outside a monitored protocol adds the side-effect burden of each drug, raises the follicle count unpredictably, and makes the twin risk harder to control — the exact problem you were trying to solve. If a cycle failed, the productive question is why (no ovulation? thin lining? poor timing?) rather than what else can I add.
Clomid alternatives, ranked by evidence
“Clomid alternative” is a broad query, so here is the full menu with the strength of evidence behind each.
- Letrozole — the best-supported alternative, and first-line in PCOS. Covered in full above and in our letrozole guide.
- Tamoxifen — another SERM, similar ovulation rates to clomiphene, occasionally used when clomiphene causes intolerable side effects. Weaker modern data; not a first choice.
- Injectable gonadotropins (FSH, or FSH plus hMG) — the most effective oral-alternative for unexplained infertility (32.2% live birth per cycle in AMIGOS) but the most expensive and the highest multiple-pregnancy rate at 32%. Requires ultrasound monitoring.
- Metformin — not an ovulation drug on its own, but additive in insulin-resistant PCOS, particularly at higher BMI.
- Laparoscopic ovarian drilling — surgical, for clomiphene-resistant PCOS; comparable ovulation rates to gonadotropins in selected patients without the multiple-pregnancy risk.
- IVF — the definitive step when three to four oral or IUI cycles fail, or when tubal factor, severe male factor or age-related egg reserve makes further waiting costly.
Our fertility drugs overview compares all of these on live birth, twin risk and cost; the alternatives to IVF guide prices the non-IVF routes.
Cost: clomiphene is cheaper per tablet, letrozole is cheaper per baby
Both are off-patent generic tablets costing tens of dollars per five-day course. That is not where the money goes.
| Item | Typical cost per cycle (US) |
|---|---|
| Oral tablet (either drug) | $10–$50 |
| Monitoring ultrasound (1–2 scans) | $150–$400 |
| Trigger injection | $50–$150 |
| Total, medication plus monitoring | $50–$500 |
The tablet price is nearly identical worldwide; monitoring fees are not, and they vary more by country than by drug. If you are comparing clinics, ask for the medication and the monitoring as two separate lines — a clinic quoting “$30 for the pills” and charging $600 for scans is not the cheaper option.
The more useful economic comparison is cost per live birth. At 27.5% versus 19.1% cumulative over five cycles, letrozole delivers roughly 44% more live births for the same tablet cost and the same number of monitoring visits. Cheaper per pill, more expensive per baby.
How many cycles before you switch?
The accepted answer for oral stimulation plus IUI as first-line therapy is three to four cycles, then IVF for those who have not conceived — the ASRM position, quoted directly:
“For most couples, the best initial therapy is a course (typically 3 or 4 cycles) of ovarian stimulation with oral medications and intrauterine insemination (OS-IUI) followed by in vitro fertilization for those unsuccessful with OS-IUI treatments.” — ASRM Practice Committee, Fertility and Sterility, 2020, PMID 32106976
Two clarifications that change the arithmetic. First, switching drugs does not restart the clock — three failed clomiphene cycles followed by three letrozole cycles is six cycles of first-line treatment, not two separate fair trials. Second, a cycle in which you did not ovulate is not a failed cycle of treatment; it is a failed dose. Escalate within the drug before you change the drug.
Agree the exit plan — the switch point, the lining threshold, the follicle number at which you cancel — before cycle one. Our IUI versus IVF comparison maps the fork, and the IUI procedure guide walks a full monitored cycle.
FAQ
Q: Is letrozole better than Clomid for getting pregnant?
Only if you have PCOS. In PCOS, letrozole produces 27.5% versus 19.1% cumulative live birth over five cycles and is now first-line. In unexplained infertility with normal ovulation, the AMIGOS trial found clomiphene at 23.3% versus letrozole at 18.7% live birth per cycle. The diagnosis, not the drug’s reputation, decides.
Q: Is Femara the same as letrozole?
Yes. Femara is the brand name for letrozole; Clomid and Serophene are brand names for clomiphene citrate. “Clomid vs Femara” is the same comparison as “clomid vs letrozole”. They are not interchangeable at the pharmacy: the starting dose is 2.5 mg for letrozole and 50 mg for clomiphene, a twentyfold difference in milligrams that reflects two entirely different mechanisms.
Q: Which one causes more twins?
Clomiphene. Its FDA label reports multiple gestation in 7.98% of trial pregnancies (6.9% twins), and PPCOS II found twins in 7.4% of clomiphene pregnancies versus 3.4% with letrozole. Pooled data give a multiple-pregnancy risk ratio of 0.42 favouring letrozole. Twin risk tracks how many follicles you grow, so monitoring and cancellation rules matter more than the drug label.
Q: Can I switch from Clomid to letrozole mid-cycle?
No. Both are five-day courses started in the first days of a cycle (day 2 to day 6 in most protocols), and switching mid-cycle would expose you to two mechanisms at once with no evidence behind the combination. A switch happens between cycles, after a washout, with a plan for monitoring.
Q: Do I need ultrasound monitoring with either drug?
Yes, and this is the most common quality gap in oral induction. Clomiphene can produce a good follicle with a lining too thin to implant, and you cannot detect that from home: a lining under about 7 mm at mid-cycle is the point where most clinicians stop escalating and reconsider the drug. One mid-cycle scan plus a progesterone check or ovulation test confirms both that ovulation happened and that the lining is adequate. Unmonitored cycles are defensible mainly in anovulatory patients with irregular or absent periods.
Q: Can men take letrozole instead of Clomid?
Clomiphene is the better-evidenced off-label option for male factor infertility: 25–50 mg daily, with monitoring of FSH, LH and testosterone. A retrospective series of 151 men found sperm concentration rose from 14 to 21 million/mL (p < 0.05), and a third of men starting below 5 million motile sperm crossed above that threshold — Andrologia, 2019. Letrozole is also used off-label in men, but the trial base is thinner. Neither should be started without a fertility urologist; our semen analysis guide covers the evaluation that should come first.
Q: Which is better if I have PCOS and a high BMI?
Letrozole still wins on live birth — 27.5% versus 19.1% in PPCOS II, a trial whose participants were mostly obese — but response falls with rising BMI for both drugs, so dose escalation and monitored cycles matter more than the choice. PPCOS II started at 2.5 mg of letrozole or 50 mg of clomiphene and escalated to 5 mg and 150 mg in later cycles. If baseline testosterone is high, the letrozole advantage widens. If you have very high AMH and severe PCOS, expect that oral agents may not be enough and plan the injectable step in advance.
Q: How long do the side effects last?
Clomiphene has a terminal half-life of about 5 days and can stay active for weeks — five half-lives is roughly 25 days — so hot flushes, mood changes and bloating may persist past the five-day course and into the luteal phase. Letrozole’s half-life is about 42 hours, and most side effects resolve within a few days of the last tablet. Visual symptoms on clomiphene are the exception that warrants stopping immediately rather than waiting.
Planning your next step
The clomid-versus-letrozole decision is a fifteen-minute conversation with a reproductive endocrinologist and a five-minute decision with the trial data in front of you — provided someone has actually established your diagnosis first.
- Get the diagnosis in writing. Anovulatory PCOS and unexplained infertility point to opposite drugs. “Infertility” is not a diagnosis.
- Ask what your lining measured on any clomiphene cycle. Under 7 mm, ask about switching rather than escalating.
- Ask whether you ovulated, not whether you “responded”. A progesterone level or a mid-cycle scan turns an impression into a data point.
- Set the switch point before cycle one — typically three to four cycles, per ASRM.
- Request separate pricing for the tablet, the scans and the blood work. They vary far more by country than by drug.
If you are deciding where to run a monitored induction or IUI cycle — at home or abroad — browse verified clinic profiles with published success rates, pricing and patient reviews, or contact our team to match your diagnosis to clinics that treat it. The medication overview and PCOS guide cover the rest of the pathway.
Disclaimer: this article is for education only and is not medical advice. Clomiphene citrate and letrozole are prescription drugs and must be taken under the supervision of a licensed reproductive endocrinologist or fertility specialist.
Success rates and side-effect incidences quoted above are population-level figures from the cited studies and cannot predict any individual’s outcome. Do not start, stop or adjust any fertility medication without consulting your own clinical team.
Written by the ProIVF Medical Editorial Team, reviewed by the ProIVF Medical Advisory Board; figures come from the linked primary sources.
Last updated: 2 November 2026